恩华药业(002262.SZ)：2025年中报净利润为7.00亿元

Core Insights - Enhua Pharmaceutical (002262.SZ) reported a total revenue of 3.01 billion yuan for the first half of 2025, with a net profit attributable to shareholders of 700 million yuan [1] Financial Performance - The company's operating cash flow decreased by 127 million yuan compared to the same period last year, representing a year-on-year decline of 20.43% [1] - The latest asset-liability ratio stands at 13.01%, an increase of 0.87 percentage points from the same period last year [2] - The gross profit margin is reported at 75.24%, while the return on equity (ROE) is 9.13%, down by 0.20 percentage points year-on-year [3] - The diluted earnings per share are 0.69 yuan [4] - The total asset turnover ratio is 0.35 times, a decrease of 0.02 times compared to the same period last year, reflecting a year-on-year decline of 5.36% [4] - The inventory turnover ratio is 1.06 times, down by 0.22 times year-on-year, indicating a decline of 17.37% [4] Shareholder Structure - The number of shareholders is reported at 43,600, with the top ten shareholders holding a total of 550 million shares, accounting for 54.16% of the total share capital [4] - The largest shareholder, Xuzhou Enhua Investment Co., Ltd., holds 31.50% of the shares [4]